For patients

Our goal is to continuously improve our signature recognition to detect Parkinson’s from a blood test at an earlier stage before motor symptoms occur.

Blood receives signals from our brain and other organs. These signals induce molecular changes in the blood that can provide information on brain health. PARKS utilizes an approach that allows us to discriminate between Parkinson’s disease and non-Parkinson’s movement disorders with overlapping symptoms.

In addition to assisting diagnosis, this technology can be used to improve patient screening for clinical trials, thereby reducing the risk for investment in new treatments for Parkinson’s.